Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib
نویسندگان
چکیده
منابع مشابه
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second li...
متن کاملAttenuation of liver stiffness in sorafenib-treated patients with advanced hepatocellular carcinoma
1Department of Radiology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan 333, Taiwan. 2Department of Surgery, Xiamen Chang Gung Hospital, Xiamen 361000, Fujian, China. 3Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan 333, Taiwan. 4Department of Nuring, Ch...
متن کاملComplete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the port...
متن کاملFactors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated fro...
متن کاملEarly α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
BACKGROUND It is not clear whether tumor marker responses can predict survival during sorafenib treatment in hepatocellular carcinoma (HCC). We investigated whether the α-fetoprotein (AFP) response is associated with survival in patients with advanced HCC treated with sorafenib. METHODS We retrospectively reviewed the records of 126 patients with advanced HCC treated with sorafenib between 20...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Gastrointestinal Oncology
سال: 2016
ISSN: 2078-6891,2219-679X
DOI: 10.21037/jgo.2015.10.07